PhD Scientific Days 2017

Oral Presentations: Clinical Sciences

Serotype comparison of carried versus clinical isolates from 2015-2016 in the era of pneumococcal conjugated vaccines in Hungary

Előadó neve

Kovács, Eszter

Előadó munkahelye

Semmelweis University, Institut of Medical Microbiology

Előadó telefonszáma

70/5962513

Előadó e-mail címe

szter55@gmail.com

Az előadás címe

Serotype comparison of carried versus clinical isolates from 2015-2016 in the era of pneumococcal conjugated vaccines in Hungary

Szerző(k) neve és munkahelye

Eszter Kovács 1, Adrienn Tóthpál 1, Csenge Török 1, Szilvia Kardos 1, Judit Sahin-Tóth 1, Orsolya Dobay 1, Tamás Tirczka 2, Mark van der Linden 3
1 Semmelweis University, Budapest
2 National Center for Epidemiology, Budapest
3 German National Reference Center for Streptococci, Aachen

Szekció

Oral Presentations: Clinical Sciences

Data of the presenter

Doctoral School: Pathological Sciences
Program: Study of the Immunbiological Effects of Microorganisms and of their Components at Molecular and Cellular Level and in the Microorganisms
Supervisor: Orsolya Dobay
E-mail address: szter55@gmail.com

Text of the abstract

Introduction
Streptococcus pneumoniae can cause severe infections mainly in children ≤5 years and in the elderly. Asymptomatic carriers - especially children - are major reservoirs of infection. Conjugated vaccines (PCVs) have an effect on both pneumococcal diseases and carriage, containing 7/10/13 serotypes from the known 94. PCV7 became recommended in 2009 in Hungary; it was later replaced by PCV13, which is mandatory since 2014.
Aims
Our aim was to demonstrate vaccine efficacy both in carriers and in patients, and to monitor serotype replacement after the implementation of PCVs in Hungary.
Methods
Clinical isolates (n=155) derived from the central laboratory of Semmelweis University, carried isolates (n=206) from screening 522 children attending nurseries, between 03-2015 and 05-2016. Serotyping was based on latex agglutination and PCR, the antibiotic sensitivity was measured by agar dilution. Group 1 comprised the carriers (n=206, <7 years), group 2 patients aged <7y (n=64) and group 3 patients ≥7y (n=91).
Results
PCV13 coverage was 7.8%, 17.2% and 30.8% in group 1, 2 and 3, respectively. In group 1, only 19A, 19F and 9V represented the PCV13 serotypes. In group 2, an elevated number of serotype 3 was observed next to 19A and 19F, meanwhile in group 3, serotype 3 was predominant. Regarding antibiotic sensitivity, higher MIC values were measured for clinical strains (e.g. levofloxacin resistance was 0,0%, 6,3% and 16,5% in group 1, 2, and 3).
Conclusion
In the surely vaccinated people (groups 1 and 2), the effect of PCVs is obvious, and PCV13 coverage in group 3 is still lower than that of invasive cases in 2015 (58%). We can conclude that serotype replacement is continuing, but fortunately these non-vaccine types are sensitive to antibiotics. The previously threatening multiresistant 19A strains show decreasing tendency and other PCV13 serotypes (19F, 3) are present mainly in older people.

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1171

Authors (legacy)

Eszter Kovács 1, Adrienn Tóthpál 1, Csenge Török 1, Szilvia Kardos 1, Judit Sahin-Tóth 1, Orsolya Dobay 1, Tamás Tirczka 2, Mark van der Linden 3
1 Semmelweis University, Budapest
2 National Center for Epidemiology, Budapest
3 German National Reference Center for Streptococci, Aachen